These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38390615)

  • 21. Genetic deletion of microglial Panx1 attenuates morphine withdrawal, but not analgesic tolerance or hyperalgesia in mice.
    Burma NE; Leduc-Pessah H; Trang T
    Channels (Austin); 2017 Sep; 11(5):487-494. PubMed ID: 28745932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxycodone physical dependence and its oral self-administration in C57BL/6J mice.
    Enga RM; Jackson A; Damaj MI; Beardsley PM
    Eur J Pharmacol; 2016 Oct; 789():75-80. PubMed ID: 27393461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How Motivations for Using Buprenorphine Products Differ From Using Opioid Analgesics: Evidence from an Observational Study of Internet Discussions Among Recreational Users.
    Butler SF; Oyedele NK; Dailey Govoni T; Green JL
    JMIR Public Health Surveill; 2020 Mar; 6(1):e16038. PubMed ID: 32209533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Behavioral Effects of Opioid Full and Partial Agonists During Chronic Buprenorphine Treatment.
    Withey SL; Spealman RD; Bergman J; Paronis CA
    J Pharmacol Exp Ther; 2019 Nov; 371(2):544-554. PubMed ID: 31413139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective M
    Teal LB; Bubser M; Duncan E; Gould RW; Lindsley CW; Jones CK
    Neuropharmacology; 2023 Apr; 227():109424. PubMed ID: 36720403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management.
    Pergolizzi JV; Raffa RB; Rosenblatt MH
    J Clin Pharm Ther; 2020 Oct; 45(5):892-903. PubMed ID: 31986228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delta-opioid receptor antagonist naltrindole reduces oxycodone addiction and constipation in mice.
    Yang PP; Yeh TK; Loh HH; Law PY; Wang Y; Tao PL
    Eur J Pharmacol; 2019 Jun; 852():265-273. PubMed ID: 30959048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful buprenorphine transition while overlapping with a full opioid agonist to treat chronic pain: a case report.
    Patel KV; Sahni S; Taylor LF
    J Osteopath Med; 2023 Jan; 123(1):1-5. PubMed ID: 36282967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
    Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
    Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dietary Supplementation with Omega-3 Polyunsaturated Fatty Acids Reduces Opioid-Seeking Behaviors and Alters the Gut Microbiome.
    Hakimian JK; Dong TS; Barahona JA; Lagishetty V; Tiwari S; Azani D; Barrera M; Lee S; Severino AL; Mittal N; Cahill CM; Jacobs JP; Walwyn WM
    Nutrients; 2019 Aug; 11(8):. PubMed ID: 31416242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic oxycodone induces integrated stress response in rat brain.
    Fan R; Schrott LM; Snelling S; Ndi J; Arnold T; Korneeva NL
    BMC Neurosci; 2015 Sep; 16():58. PubMed ID: 26377394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of supraspinal and peripheral naloxonazine-insensitive opioid receptor sites in the expression of μ-opioid receptor agonist-induced physical dependence.
    Mori T; Komiya S; Uzawa N; Inoue K; Itoh T; Aoki S; Shibasaki M; Suzuki T
    Eur J Pharmacol; 2013 Sep; 715(1-3):238-45. PubMed ID: 23707904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Δ
    Slivicki RA; Wang JG; Nhat VTT; Kravitz AV; Creed MC; Gereau RW
    bioRxiv; 2023 Dec; ():. PubMed ID: 38105953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minocycline attenuates oxycodone-induced positive subjective responses in non-dependent, recreational opioid users.
    Mogali S; Askalsky P; Madera G; Jones JD; Comer SD
    Pharmacol Biochem Behav; 2021 Oct; 209():173241. PubMed ID: 34298029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ketogenic diet enhances the effects of oxycodone in mice.
    Trinko R; Diaz DM; Foscue E; Thompson SL; Taylor JR; DiLeone RJ
    Sci Rep; 2023 May; 13(1):7507. PubMed ID: 37160959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strain and sex-related behavioral variability of oxycodone dependence in rats.
    Doyle MR; Martinez AR; Qiao R; Dirik S; Di Ottavio F; Pascasio G; Martin-Fardon R; Benner C; George O; Telese F; de Guglielmo G
    Neuropharmacology; 2023 Oct; 237():109635. PubMed ID: 37327971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine D
    de Guglielmo G; Kallupi M; Sedighim S; Newman AH; George O
    Front Behav Neurosci; 2019; 13():292. PubMed ID: 31992976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute opioid withdrawal syndrome from naloxone/naloxegol interaction.
    Olmo M; González-Barboteo J; Moreno D; Coma E; Serrano G
    BMJ Support Palliat Care; 2021 Dec; 11(4):408-410. PubMed ID: 32788278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is the Neuroimmune System a Therapeutic Target for Opioid Use Disorder? A Systematic Review.
    Toloff K; Woodcock EA
    Med Res Arch; 2022 Aug; 10(8):. PubMed ID: 37744743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex.
    Chindalore VL; Craven RA; Yu KP; Butera PG; Burns LH; Friedmann N
    J Pain; 2005 Jun; 6(6):392-9. PubMed ID: 15943961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.